Covance Enhances IVR Services with State-of-the-Art Interactive Web Response (IWR) Powered by Clarix
|View printer-friendly version||<< Back|
— Advanced IVRS/IWRS offers leading-edge functionality over the phone and web —
Princeton, NJ, September 17, 2007 — Covance Inc. (NYSE: CVD) today announced the addition of a state-of-the-art Interactive Web Response service for randomization and drug supply management, powered by Clarix IVRS R4. This new service offers customers leading-edge IVR/IWR technology solutions and access to the clinical resources and expertise of one of the world's largest drug development services companies.
"Nowhere else in the market today can IVR/IWR customers get access to project managers with such a wealth of resources on hand, whether that be in-house PhD statisticians and physicians, or state-of-art technology solutions, such as this," said Brian O'Callaghan, General Manager & Vice President, Covance IVRS & Cardiac Safety Services. "We provide customers the unique combination of world-class technology, in-depth clinical trial expertise and extensive multinational clinical resources. A service offering with leading-edge technology and access to this degree of clinical trial know-how is not available anywhere else in the industry."
As one of the only full-service drug development services company with a dedicated, in-house IVR system, Covance designs and develops IVR technology solutions to help customers manage patient screening and enrollment, randomization, and drug supply management from a clinical perspective.
The Clarix IVR/IWR technology platform sets the standard for clinical technology solutions in the industry and enables Covance to expand its delivery of technological and clinical expertise to the web.
"The Clarix IVRS R4 is the most advanced fully web-integrated IVRS in the industry today. It offers unparalleled deployment speed, leading-edge functionality, and powerful reporting capability," said Jagath Wanninayake, Chief Executive Officer and Founder of Clarix. "Our advanced IVR/IWR product, coupled with the depth of Covance IVRS project management expertise, is a very compelling value proposition for Covance customers."
Covance has provided IVRS to the pharmaceutical, biotechnology and medical device industries since 1989 and was the first to apply the technology to the clinical trial process. Covance IVRS uses industry-proven evolving technologies and superior consultative service to develop innovative methods for supporting clinical trials. Covance provides comprehensive IVRS and related support services tailored to meet the needs of each clinical protocol and add value to every program using IVRS.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and greater than 8,500 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Clarix LLC is a company providing an innovative suite of eClinical software products including the most advanced, fully web-integrated IVRS in the industry. Clarix applications are designed for rapid deployment, flexibility, and advanced real-time reporting capability. Clarix IVRS and EDC products are currently being used by clinical sites in over 40 countries on 6 continents. For more information about Clarix, please visit www.clarixinformatics.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission. Covance and the Covance are registered service marks of Covance in the United States and other countries.